Fermenta Biotech Publishes Q1 FY27 Unaudited Financial Results
Fermenta Biotech released its unaudited Q1 FY27 results for the quarter ended June 30, 2026. Consolidated total income was ₹12,619.50 lakh and net profit was ₹953.15 lakh. Standalone total income was ₹11,673.59 lakh and net profit was ₹1,498.58 lakh. The results were published in newspapers on August 12, 2026.
This is a standard disclosure of financial results, which is a routine regulatory requirement and does not provide new strategic information or significant financial performance changes that would impact the company's stock.
The announcement is a routine publication of financial results and newspaper advertisements, with no significant positive or negative developments indicated.
Fermenta Biotech Limited has announced the publication of its unaudited financial results for the quarter ended June 30, 2026. The results, which include both standalone and consolidated figures, were published in the Business Standard (English) and Sakal (Marathi) newspapers on August 12, 2026. This announcement follows up on a previous intimation dated August 11, 2026, regarding the declaration of these financial results.
The company provided a detailed breakdown of its financial performance for the quarter. For the consolidated results, total income from operations was ₹12,619.50 lakh, with profit before tax at ₹1,469.15 lakh. Net profit after tax stood at ₹953.15 lakh. Standalone figures showed total income from operations at ₹11,673.59 lakh, profit before tax at ₹2,014.58 lakh, and net profit after tax at ₹1,498.58 lakh.
These results are an extract of the detailed financial results filed with the stock exchanges and are available on the websites of BSE, NSE, and Fermenta Biotech's corporate website. The company has also provided earnings per share (EPS) data for both basic and diluted figures, before and after exceptional items, for the quarter ended June 30, 2026, and comparative periods.
What to do with a filing like this
Fermenta Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fermenta Biotech Limited. Read the original for the full detail.